Eli Lilly and Co. and Incyte Corp. said their rheumatoid arthritis drug baricitinib did not meet the main goal of preventing progression to mechanical ventilation in hospitalized Covid-19 patients under a late-stage study.
A legal complaint was filed against Alvotech for the Icelandic pharmaceutical company’s alleged misappropriation of trade secrets involving the development of a generic version of AbbVie’s rheumatoid arthritis drug Humira.
The U.S. Food and Drug Administration extended the review period for expanded use of Abbvie Inc.’s rheumatoid arthritis drug Rinvoq by three months, citing the need for more time to assess the drug’s benefit-risk profile.
The U.S. Food and Drug Administration approved Genentech’s Actemra (tocilizumab) for slowing the rate of decline in pulmonary function in adults with systemic sclerosis-associated interstitial lung disease (SSc-ILD).
Pfizer announced in a statement that the prespecified non-inferiority criteria for a post-marketing safety study of the rheumatoid arthritis drug Xeljanz (tofacitinib) were not met, but the company remains hopeful that future analyses of the study will be more promising.
The U.S. Food and Drug Administration granted Emergency Use Authorization to a combination of Eli Lilly’s and Incyte’s rheumatoid arthritis drug Olumiant (baricitinib) and Gilead Sciences’ remdesivir as a treatment for hospitalized patients diagnosed with Covid-19 who require supplemental oxygen or ventilation.
Eli Lilly and Co. said the company’s rheumatoid arthritis drug baricitinib shortened the recovery time for hospitalized Covid-19 patients also given Gilead Sciences Inc.’s antiviral remdesivir.
French drugmaker Sanofi and Britain’s GlaxoSmithKline started a clinical trial of their protein-based Covid-19 vaccine candidate, with the companies aiming to reach the final testing stage by December.
A recent report in the New England Journal of Medicine reveals that the racial and ethnic minority groups most negatively impacted by Covid-19 are also the least represented in these clinical studies to develop vaccines and therapeutics aimed at the disease.
Roche’s attempt to retool the company’s rheumatoid arthritis drug Actemra/RoActemra to treat patients hospitalized with severe Covid-19-related pneumonia failed in a late-stage trial.